September 30, 2025 — Gilead’s Epclusa (sofosbuvir/velpatasvir, 400mg/100mg) continues to reshape hepatitis C management worldwide. As the first and only all-oral, pan-genotypi...
The U.S. Food and Drug Administration has granted approval to Otsuka’s newly developed injectable therapy for patients diagnosed with primary immunoglobulin A nephropathy (IgAN), ...